Chronic pain
Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate
Ambros Therapeutics; $125 million Series A; chronic pain; complex regional pain syndrome type 1; CRPS-1; neridronate; non-opioid analgesic; bisphosphonate; Vivek Ramaswamy; biotech financing
FDA Approves Tonix’s Tonmya: First New Fibromyalgia Drug in Over 15 Years
Tonmya; FDA approval; fibromyalgia; Tonix Pharmaceuticals; non-opioid analgesic; cyclobenzaprine HCl sublingual tablets; chronic pain; phase 3 clinical trials
Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline
Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain
Abbott’s Spinal Cord Stimulation Systems Demonstrate Long-Term Efficacy in Chronic Pain Management
Abbott, spinal cord stimulation, chronic pain, BurstDR stimulation, Proclaim Plus, Proclaim XR, FDA approval, non-surgical back pain